Linda Anne Feagins MD

Annie Feagins, M.D., is an associate professor in the Department of Internal Medicine at Dell Medical School, a board-certified gastroenterologist and director of the Center of Inflammatory Bowel Disease at Digestive Health, a clinical partnership between Dell Med and Ascension Seton. Before joining Dell Med, Feagins was an associate professor at The University of Texas Southwestern Medical Center and VA Hospital in Dallas. She was also the director of the inflammatory bowel disease program at the VA North Texas from 2008 until 2019.

Feagins has done research on preventing post-polypectomy bleeding during colonoscopy. With competitive grant funding from VA Hospital, she published the first prospective estimates of the rates of post-polypectomy bleeding with uninterrupted use of antiplatelets. She also led a large multi-center trial investigating the role of prophylactic hemoclips to prevent delayed bleeding. The study found that hemoclips did not reduce the risk of bleeding when placed after removal of polyps 1cm in size or larger. The study was published in Gatroenterology.

Feagins’ other area of research interest is in improving care for patients with IBD. Her projects include predicting the risk of flare up for patients with IBD using histology and biomarkers (such as epithelial tight junction proteins), better understanding the onset and course of IBD in older patients, sexual health in men with IBD, role of diet in IBD and the effects of radiation for prostate cancer in men with IBD. In addition to ongoing investigator-initiated studies, she is building a sponsored clinical trials program for IBD at Dell Med to bring new therapy options for patients in Austin. Feagins has served on several National Scientific Advisory Committees for the Crohn’s and Colitis Foundation, FDA Related Matters Committee for the American College of Gastroenterology and abstract review committee for the American Gastroenterological Association. She also served five years on the Gastrointestinal Drug Advisory Board for the FDA.